Showing results (1181-1190 of 2,132) with videos related to
Sort By:
Pageof 214
Biopharmaceutics & Drug Disposition|December 23, 2003
Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytesAnima Ghosal, Neil Hapangama, Yuan Yuan, et al.Biopharmaceutics & Drug Disposition|December 23, 2003
Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in ratsHyun J Shim, Yu C Kim, Ji M Jang, et al.Biopharmaceutics & Drug Disposition|January 13, 2004
Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseasesHugo Juárez Olguín, Janett Flores Pérez, Ismael Lares Asseff, et al.Biopharmaceutics & Drug Disposition|June 27, 2019
Identification of sulfonyl-loxoprofen as novel phase 2 conjugate in ratRiya Shrestha, Sanjita Paudel, Piljoung Cho, et al.Biopharmaceutics & Drug Disposition|April 16, 2019
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairmentKentaro Konishi, Tsuyoshi Minematsu, Yasuhisa Nagasaka, et al.Biopharmaceutics & Drug Disposition|May 24, 2018
Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's diseaseKoji Kimura, Atsushi Yoshida, Risa Takayanagi, et al.Biopharmaceutics & Drug Disposition|July 1, 1989
Pharmacokinetic interaction between diltiazem and amiodarone in the dogJ Ben David, M BialerBiopharmaceutics & Drug Disposition|April 22, 2018
Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasisMysore S Anil Kumar, Kim Papp, Ryo Tainaka, et al.Biopharmaceutics & Drug Disposition|July 4, 2017
Clinical assessment of the lag-time and tmax of pellets with controlled release of glucose: in vitro/in vivo comparison using 13 C-breath testDavid Neumann, Jan Muselík, Dana Sabadková, et al.Biopharmaceutics & Drug Disposition|September 2, 2018
CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisibStefan De Buck, Klaus Kucher, Hisanori Hara, et al.Pageof 214